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Summary
Background.  —  Severe  pulmonary  hypertension  is  a  usual  contraindication  to  heart  transplanta-
tion. A  few  studies  have  found  that  sildenaﬁl  has  a  favourable  effect  on  haemodynamic  variablestransplantation; in patients  with  severe  left  ventricular  systolic  dysfunction.
Pulmonary
hypertension;
Sildenaﬁl
Aim.  —  To  report  our  clinical  experience  of  sildenaﬁl  in  patients  with  left  ventricular  systolic
dysfunction  and  severe  pulmonary  hypertension.
Methods.  —  All  patients  underwent  echocardiography,  radionuclide  angiography,  a  cardiopul-
monary exercise  test  and  right  heart  catheterization  before  and  after  treatment  with  sildenaﬁl.
Abbreviations: LVAD, left ventricular assist device; LVSD, left ventricular systolic dysfunction; mPAP, mean pulmonary artery pressure;
PAWP, pulmonary artery wedge pressure; PVR, pulmonary vascular resistance; WU, Wood units.
∗ Corresponding author. Pôle cardio-vasculaire et pulmonaire, service de cardiologie, hôpital cardiologique, boulevard Prof. J.-Leclercq,
CHRU de Lille, 59037 Lille cedex, France.
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All  patients  were  clinically  stable  and  were  receiving  maximal  tolerated  doses  of  recommended
drugs.
Results. —  We  included  18  patients,  with  a  mean  ±  standard  deviation  age  of  47  ±  13  years.
After a  median  of  8.7  months  (interquartile  range,  4.4—13.5  months)  on  sildenaﬁl,  there  was
a signiﬁcant  improvement  in  New  York  Heart  Association  classiﬁcation  (P  =  0.02)  and  mean
right ventricular  ejection  fraction  (from  26  ±  7%  to  30  ±  9%;  P  =  0.008),  with  a  decrease  in  the
VE/VCO2 slope  (from  52  ±  11  to  44  ±  11;  P  =  0.009)  and  in  pulmonary  vascular  resistance  (from
5.3 ±  1.9  Wood  units  to  3.3  ±  1.8  Wood  units;  P  =  0.01).  During  follow-up,  three  patients  had
urgent heart  transplantation,  two  had  non-urgent  transplantation  and  six  had  left  ventricular
assist device  implantation.  All  patients  with  pulmonary  vascular  resistance  <  3  Wood  units  after
sildenaﬁl were  alive,  compared  with  four  in  the  other  subgroup  (44%  survival).
Conclusion.  —  In  patients  with  pulmonary  hypertension  related  to  left  ventricular  systolic  dys-
function, sildenaﬁl  seems  to  improve  cardiac  haemodynamics.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  La  présence  d’une  hypertension  pulmonaire  sévère  est  une  contre-indication
habituelle  à  la  transplantation  cardiaque.  Quelques  études  ont  montré  des  effets  hémody-
namiques favorables  du  sildénaﬁl  chez  des  patients  avec  une  dysfonction  systolique  sévère  du
ventricule  gauche.
Objectif.  —  De  présenter  notre  expérience  du  sildénaﬁl  chez  des  patients  présentant  une  dys-
fonction systolique  du  ventricule  gauche  et  une  hypertension  pulmonaire  sévère.
Méthodes.  —  Tous  les  patients  ont  réalisé  avant  et  après  l’introduction  de  sildénaﬁl  une  échogra-
phie cardiaque,  une  angiographie  ventriculaire  isotopique,  une  épreuve  d’effort  métabolique
et un  cathétérisme  cardiaque  droit.  Tous  les  patients  étaient  cliniquement  stables  et  tous
recevaient  un  traitement  recommandé,  aux  doses  maximales  tolérables.
Résultats.  —  Nous  avons  inclus  18  patients  avec  une  moyenne  d’âge  de  47  ±  13  ans.  Après  8,72
mois (4,4—13,5)  sous  sildénaﬁl,  on  a  constaté  une  amélioration  signiﬁcative  de  la  classiﬁcation
NYHA (p  =  0,02)  et  de  la  fraction  d’éjection  du  ventricule  droit  (26  ±  7  %  à  30  ±  9  %  ;  p  =  0,008)
avec une  diminution  de  la  pente  de  VE/VCO2 (52  ±  11  à  44  ±  11  ;  p  =  0,009)  et  une  diminution  des
résistances  vasculaires  pulmonaires  (RVP)  (5,3  ±  1,9  à  3,3  ±  1,8  unités  Wood  ;  p  =  0,01).  Pendant
le suivi,  3  patients  ont  pu  bénéﬁcier  d’une  transplantation  en  urgence,  2  d’une  transplantation
non urgente,  6  de  l’implantation  d’une  assistance  monoventriculaire  gauche.  Tous  les  patients
avec des  RVP  <  3  unités  Wood  après  sildénaﬁl  sont  vivants,  alors  que  seuls  4  le  sont  dans  l’autre
groupe (44  %  de  survie).
Conclusion.  —  Le  sildénaﬁl  semble  améliorer  les  données  hémodynamiques  chez  des  patients
avec une  hypertension  pulmonaire  sévère  secondaire  à  une  dysfonction  systolique  du  ventricule
gauche.
© 2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
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orbimortality  remains  elevated  despite  improvements
n  the  therapeutic  management  of  patients  with  heart
ailure  related  to  left  ventricular  systolic  dysfunction  (LVSD)
1—5].  Heart  transplantation  is  required  in  some  patients,
ut  the  low  number  of  heart  donors  is  a  major  limiting
actor  preventing  the  widespread  use  of  this  approach.
ecause  of  this  limitation,  the  implantation  of  a left
entricular  assist  device  (LVAD)  as  a  bridge  to  transplan-
ation  is  sometimes  required.  For  some  young  patients  in
hom  heart  transplantation  is  contraindicated  because
f  non-cardiac  comorbidities,  a  LVAD  can  be  implanted
p
i
reﬁnitively  as  a destination  therapy.  Heart  transplantation
r  LVAD  implantation  are  effective  therapies,  but  with  a
igh  operative  risk.  Thus,  the  selection  of  candidates  for
hese  alternative  therapies  must  be  performed  carefully.
ne  major  contraindication  to  heart  transplantation  is  the
resence  of  severe  pulmonary  hypertension  [6,7].  Currently,
e  do  not  have  effective  drugs  that  have  demonstrated  a
igniﬁcant  effect  on  post-capillary  pulmonary  hypertension.
ome  studies  in  patients  with  post-capillary  pulmonary
ypertension  have  reported  the  usefulness  of  sildenaﬁl,  a
hosphodiesterase  type  V inhibitor,  extensively  prescribed
n  patients  with  pulmonary  arterial  hypertension  [8,9].  We
eport  our  clinical  experience  with  sildenaﬁl  in  patients
n
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with  LVSD  and  with  severe  pulmonary  hypertension  and
elevated  pulmonary  vascular  resistance  (PVR).
Methods
Study population
We  included  in  this  analysis  all  patients  admitted  to  our
department  between  2007  and  2013  for  a  possible  listing  for
heart  transplantation.  All  patients  had  chronic  heart  failure
related  to  LVSD  and  were  receiving  maximal  tolerated  doses
of  recommended  drugs.  For  angiotensin-converting  enzyme
inhibitors,  angiotensin  receptor  blockers  and  beta-blockers,
we  determined  the  percentage  of  maximal  recommended
doses  of  the  different  drugs,  based  on  the  most  recent  Euro-
pean  guidelines  [10].  Patients  underwent  echocardiography,
radionuclide  angiography,  a  cardiopulmonary  exercise  test
and  right  heart  catheterization.
Haemodynamic measurements
Right  heart  catheterization  was  performed  under  local
anaesthesia,  either  by  the  brachial  or  the  femoral  vein,  using
a  Swan-Ganz  catheter.  All  measurements  were  obtained
at  steady  state  with  the  patient  in  a  supine  position.
Mean  pulmonary  artery  pressure  (mPAP)  and  pulmonary
artery  wedge  pressure  (PAWP)  were  calculated  by  the  com-
puter  as  the  integrated  mean  of  the  curves.  Mixed  central
venous  blood  gas  was  sampled  from  the  pulmonary  artery.
Cardiac  output  was  determined  as  the  mean  of  three
to  seven  separate  measurements  by  the  thermodilution
technique.  PVR,  cardiac  index,  transpulmonary  gradient
(mPAP—PAWP)  and  diastolic  pressure  gradient  (diastolic  pul-
monary  pressure  —  PAWP)  were  calculated  using  standard
formulae.  After  baseline  measurements,  in  case  of  elevated
PVR  (>  3  Wood  units  [WU]),  dobutamine  infusion  was  started
at  a  dose  of  10  /kg/min  over  10  minutes  and  increased  up  to
40  /kg/min  in  case  of  insufﬁcient  response,  and  a  complete
new  haemodynamic  evaluation  was  performed.
Other measurements
Echocardiography  was  performed  with  a  Vivid  E9  (GE  Medi-
cal  Systems,  Wauwatosa,  WI,  USA)  with  the  determination
of  standard  and  Doppler  variables  according  to  the  recom-
mendations  of  the  American  Society  of  Echocardiography
[11].  Left  ventricular  ﬁlling  pressure  was  estimated  by  the
sonographer  (normal  or  increased),  as  recommended  by
the  American  Society  of  Echocardiography  [12].  Equilib-
rium  radionuclide  angiography  was  performed  at  rest  in
the  supine  position  for  the  determination  of  left  ventricu-
lar  ejection  fraction  and  right  ventricular  ejection  fraction,
using  an  ECAM  camera  (Siemens,  Erlangen,  Germany),  after
the  injection  of  740  MBq  of  technetium-99  m.  The  data  for
gas  exchange  during  the  cardiopulmonary  exercise  test  were
collected  on  a  breath-by-breath  basis  using  a  computer-
ized  system  (Vmax;  SensorMedics,  Yorba  Linda,  CA,  USA).
Peak  oxygen  consumption  was  deﬁned  as  the  highest  average
value  during  20  seconds,  obtained  during  the  last  minute  of
exercise.  The  predicted  value  of  maximal  oxygen  consump-
tion  was  calculated  using  Wasserman’s  equation.  B-type
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atriuretic  peptide  concentration  was  measured  with  the
dvia  Centaur  BNP  assay  (Bayer  Healthcare  LLC,  Tarrytown,
Y,  USA),  and  with  the  Triage  BNP  assay  (Biosite  Diagnostics,
nc.,  San  Diego,  CA,  USA)  for  the  historical  cohort.
ommittee decision
he  decision  to  add  patients  to  the  waiting  list  for
eart  transplantation  or  to  propose  an  LVAD  implanta-
ion  in  young  patients  (≤  65  years)  with  contraindication
o  heart  transplantation  was  made  by  a  committee  that
ncluded  cardiologists,  surgeons  and  anaesthesiologists,  all
f  whom  were  experts  in  heart  failure.  This  committee
stimated  the  operative  risk  for  each  patient  and  decided
o  introduce  sildenaﬁl  when  the  risk  was  estimated  to
e  excessive  because  of  at  least  the  presence  of  per-
istent  post-capillary  pulmonary  hypertension,  deﬁned  as
PAP  ≥  25  mmHg,  PAWP  > 15  mmHg  and  PVR  >  3  WU,  without
eversibility  despite  an  inotropic  challenge  with  dobutamine
PVR  ≥  3  WU  or  mPAP  ≥  35  mmHg  with  a transpulmonary  gra-
ient  ≥  12  mmHg).  Sildenaﬁl  was  started  at  a  dose  of  20  mg
hree  times  daily.  Doses  were  increased  in  case  of  non-
unctional  improvement  and  a  new  cardiac  evaluation  was
erformed  six  months  after  the  last  increase  in  sildenaﬁl
ose.
tatistical analysis
esults  are  expressed  as  means  ±  standard  deviations  or  as
edians  with  interquartile  ranges  for  variables  that  were
ot  normally  distributed.  Discrete  variables  were  compared
sing  the  Chi2 test,  with  a  Fisher’s  exact  test  if  nec-
ssary.  Comparisons  between  quantitative  variables  were
ade  using  the  non-parametric  Wilcoxon  test  for  repeated
easures  and  the  Mann—Whitney  test.  A  value  of  P  ≤  0.05
as  considered  statistically  signiﬁcant.  Statistics  were  per-
ormed  with  SPSS  software,  version  15.0  (SPSS  Inc.,  Chicago,
L,  USA).
esults
rom  January  2007  to  December  2013,  268  patients  were
dmitted  for  possible  inclusion  on  the  waiting  list  for
eart  transplantation.  The  patient  ﬂow  chart  is  presented
n  Fig.  1.  From  these  268  patients,  we  included  in  this
pen-label  study,  18  patients  suitable  for  either  heart
ransplantation  or  LVAD  implantation,  with  elevated  PVR
nd  a  high  estimated  operative  risk.  Baseline  character-
stics  are  presented  in  Table  1.  The  mean  age  of  the
tudy  population  was  47  ±  13  years,  there  were  three
omen,  one  patient  had  chronic  atrial  ﬁbrillation  and
our  patients  had  diabetes  mellitus.  LVSD  was  related  to
schaemic  cardiopathy  in  10  patients,  ﬁve  patients  had
ilated  cardiomyopathy,  one  had  anthracycline-induced  car-
iopathy,  one  had  a  valvular  heart  disease  and  the  last
atient  had  a congenital  cardiopathy  (neonatal  myocar-
ial  infarction).  Five  patients  had  complete  left  bundle
ranch  block  with  resynchronization  therapy;  17  had  an
mplantable  deﬁbrillator.  The  treatment  of  the  study  pop-
lation  is  summarized  in  Table  1.  All  patients  received
aximal  tolerated  doses  of  renin  inhibitors  (ramipril,
378
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Figure 1. Flow chart of the study population. HF: heart failure; LVAD: left ventricular assist device; pt: patient; PVR: pulmonary vascular resistance; RHC: right heart catheterization; Tx:
transplantation; WL: waiting list for heart transplantation; WU: Wood units.
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Table  1  Major  characteristics  of  the  historical  cohort  and  the  study  population  before  and  after  sildenaﬁl.
Variables  Historical  cohort  Before  sildenaﬁl  After  sildenaﬁl  P  P  (historical  vs
before  sildenaﬁl)
NYHA  class
II  4  3  10  0.02  0.73
III  12  14  8
IV  2  1  0
Heart  rate  (beats/min) 76  ±  13 70  ±  10 73  ±  11  0.21  0.06
Systolic  blood  pressure
(mmHg)
93 ±  12 99  ±  15 95  ±  12 0.34  0.82
Diastolic  blood  pressure
(mmHg)
61 ±  6  66  ±  10  60  ±  10  0.03  0.40
ACE  inhibitor  13  15  13
ARB  5  3  5
ACE  inhibitor/ARB  (%  of
maximal  doses)
71 ±  30  78.5  ±  30  85.4  ±  25.8  0.37  0.36
Beta-blocker  (%  of  maximal
doses)
61 ±  30  88  ±  38  75  ±  28  0.25  0.055
Spironolactone  11  6  10
Spironolactone  (mg/day)  25  (0—25)  25  (25—25)  25  (12.5—25)  0.32  0.61
Eplerenone  —  7  6
Eplerenone  (mg/day)  —  25  (25—50)  50  (25—50)  0.32
Furosemide  (mg/day)  80  (60—500)  100  (60—250)  160  (120—375)  0.04  0.87
LVEF  (%)  24  ±  10  24  ±  8  26  ±  7  0.1  0.70
RVEF  (%)  29  ±  9  26  ±  7  30  ±  9  0.008  0.32
LVEDD  (mm)  71  ±  9  66  ±  12  67  ±  12  0.62  0.21
LVEDV  (mL)  245  ±  130  208  ±  92  214  ±  90  0.65  0.41
Left  atrial  diameter  (mm)  47  ±  9  47  ±  7  48  ±  10  0.28  0.96
Left  atrial  surface  (cm2)  28  ±  10  30  ±  9  32  ±  11  0.33  0.73
E/A  2.3  ±  0.91  3.1  ±  1.2  3.1  ±  0.98  0.75  0.02
Mitral  deceleration  time  (s)  120  ±  19  122  ±  39  128  ±  34  0.41  0.46
E/e’  13.4  ±  5.2  22  ±  9  22  ±  11  0.87  0.004
Right  atrial  surface  (cm2)  23  ±  9  24  ±  7  24  ±  8  0.87  0.51
TAPSE  (mm)  16.2  ±  4  16.2  ±  4.5  16.4  ±  4.3  0.94  0.89
RVTiDS  (cm/s)  6.8  ±  1.44  9.5  ±  2.5  9.7  ±  2.6  0.53  0.002
Peak  VO2 (mL/min/kg) 11.6  ±  3  11.5  ±  3.8  12.4  ±  3.7  0.28  0.77
Peak  VO2 (%) 39 ±  13 39  ±  14  43  ±  16  0.08  0.95
Peak  RER 1.18  ±  0.11  1.27  ±  0.12  1.26  ±  0.12  0.87  0.10
VE/VCO2 slope 48 ±  10 52  ±  11  44  ±  10  0.009  0.63
BNP  (pg/mL)a 490  (290—1011)  877  (315—1397)  559  (270—1380)  0.22  —
Data are expressed as number, mean ± standard deviation or median (interquartile range). ACE: angiotensin-converting enzyme; ARB:
angiotensin receptor blocker; BNP: B-type natriuretic peptide; E/A: ratio between peak velocities of early and late mitral ﬁlling waves;
E/e: ratio between peak velocities of early mitral ﬁlling wave and tissue doppler early mitral diastolic annulus velocity; LVEDD: left
ventricular end diastolic diameter; LVEDV: left ventricular end diastolic volume; LVEF: left ventricular ejection fraction; NYHA: New
York Heart Association; RER: respiratory exchange ratio; RVEF: right ventricular ejection fraction; RVTiDS: tissue doppler peak systolic
tricuspid annular velocity; TAPS: tricuspid annular plane systolic excursion; VE: minute ventilation; VCO2: carbon dioxide production;
VO2: oxygen consumption; VO2%: % of maximal predicted value.
a BNP was measured with the Advia Centaur BNP assay (Bayer Healthcare LLC, Tarrytown, NY, USA) in the study population and with the
Triage BNP assay (Biosite Diagnostics, Inc., San Diego, CA, USA) in the historical cohort.
[
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o7.1  ±  3.3  mg/day  [n  =  7];  perindopril,  8.3  ±  2  mg/day  [n  =  8])
and  beta-blockers  (bisoprolol,  9.2  ±  3.7  mg/day  [n  =  15];
nebivolol,  7.5  ±  3.5  mg/day  [n  =  2]),  16  received  miner-
alocorticoid  receptor  antagonists,  which  were  introduced
after  the  ﬁrst  right  heart  catheterization  in  four  patients,
and  10  received  oral  anticoagulants.  All  patients  received
diuretics.  Doses  of  diuretics  were  increased  after  silde-
naﬁl  therapy  (furosemide,  100  [60—250]  mg/day  vs  160
t
H
s120—375]  mg/day;  P  =  0.04),  whereas  doses  of  other  drugs
emained  stable.  For  sildenaﬁl,  two  patients  received
80  mg/day,  seven  patients  received  120  mg/day  and  the
ther  patients  received  60  mg/day.The  effect  of  sildenaﬁl  on  major  clinical  characteris-
ics  is  presented  in  Table  1. Sildenaﬁl  improved  New  York
eart  Association  classiﬁcation  but  not  peak  oxygen  con-
umption.  However,  the  VE/VCO2 slope  was  improved,  as
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Table  2  Haemodynamic  characteristics  of  the  historical  cohort  and  the  study  population  before  and  after  sildenaﬁl.
Historical  cohort  Before  sildenaﬁl  After  sildenaﬁl  P  P  (historical  vs
before  sildenaﬁl)
Baseline
Heart  rate  (beats/min)  79  ±  15  73  ±  11  71  ±  12  0.38  0.24
mPAP  (mmHg)  43  ±  9  45  ±  6  41  ±  11  0.27  0.32
PAWP  (mmHg)  26  ±  6  28  ±  5  29  ±  9  0.27  0.24
TrPulmGr  (mmHg) 18.6  ±  8.1 16.9  ±  4.7 12.6  ±  6.8  0.03  0.65
DiastPulmGr  (mmHg) 5  (2—7) 1  (—3—6) —1  (—5—0) 0.14  0.11
Cardiac  index  (L/min/m2) 1.6 ±  0.29 1.81  ±  0.47 2.08  ±  0.42 0.04 0.10
SVO2 (%)a —  52  ±  12  59  ±  10  0.02  —
PVR  (WU)  6.6  ±  3.8  5.3  ±  1.9  3.3  ±  1.8  0.01  0.70
Right  atrial  pressure  (mmHg)  12  ±  4  13  ±  6  12  ±  7  0.29  0.99
Inotropic  challenge
Dose  of  dobutamine  (/kg/min)  32.8  ±  8.9  32.4  ±  10.9  24.7  ±  11.2  0.06  0.84
Heart  rate  (beats/min)  97  ±  16  97  ±  18  94  ±  19  0.93  0.80
mPAP  (mmHg)  40  ±  8  42  ±  11  40  ±  14  0.89  0.34
PAWP  (mmHg)  19  ±  6  23  ±  10  22  ±  12  1.00  0.71
TrPulmGr  (mmHg)  21  ±  8  20  ±  5  18  ±  5  0.84  0.66
DiastPulmGr  (mmHg)  5  (2—9)  4  (2—8)  3  (0—6)  0.33  0.41
Cardiac  index  (L/min/m2)  2.7  ±  0.5  3.1  ±  0.9  3.9  ±  0.8  0.03  0.10
SVO2 (%)a —  75  ±  6  78  ±  6  0.35
PVR  (WU)  4.3  ±  1.8  3.8  ±  1 2.6  ±  0.7  0.02  0.99
Right  atrial  pressure  (mmHg)  7  ±  3  8.6  ±  4.7  8.4  ±  5.9  0.88  0.24
DiastPulmGr: diastolic pulmonary gradient; mPAP: mean pulmonary artery pressure; PAWP: pulmonary artery wedge pressure; PVR:
pulmonary vascular resistance; SVO2: pulmonary arterial oxygen saturation; TrPulmGr: transpulmonary gradient; WU: Wood units.
a SVO was not measured before 2007.
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catheterization  was  0.74  (0.28—1.56)  years.  Patients  were
censored  at  the  time  of  heart  transplantation  or  LVAD2
as  right  ventricular  ejection  fraction  (from  26  ±  7%  to
0  ±  9%;  P  =  0.008).  There  was  no  signiﬁcant  modiﬁcation
n  echocardiographic  variables  or  B-type  natriuretic  pep-
ide  concentration.  Haemodynamic  data  before  and  after
ildenaﬁl  are  presented  in  Table  2.  The  median  duration
etween  the  two  right  heart  catheterizations  was  8.72
4.4—13.5)  months.  Fig.  2  shows  the  mean  PVR  with  and
ithout  dobutamine  infusion  and  before  and  after  silde-
aﬁl.  There  was  a  signiﬁcant  decrease  in  PVR  after  sildenaﬁl
nd  a  signiﬁcant  increase  in  cardiac  index  (and  in  venous
igure 2. Evolution of pulmonary vascular resistance (PVR) with-
ut and with dobutamine, before and after sildenaﬁl. WU: Wood
nits.
i
F
a
a
Wulmonary  saturation),  either  at  rest  or  during  dobutamine
nfusion.  Fig.  3  shows  the  individual  data  for  the  18  patients.
ollow-up
he  median  follow-up  period  after  the  second  right  heartmplantation.  Fig.  1  shows  the  ﬂow  chart  of  the  patients
igure 3. Individual pulmonary vascular resistance (PVR) without
nd with dobutamine and before and after sildenaﬁl. Red wide lines
nd numbers are individual PVRs for the ﬁve deceased patients. WU:
ood units.
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Table  3 Summary  of  the  main  results  in  previous  studies  with  sildenaﬁl  in  severe  chronic  systolic  heart  failure  patients.
Study  Year n  Sildenaﬁl  dose
(mg/day)
Treatment
duration
PVR (WU) mPAP  (mmHg) Cardiac  output  (L/min) Clinical  results
Zakliczynski
et  al.  [14]
2007  6  100  1  month 4.5  (3.1—5.6)  to  2.6
(1.5—5.4)
32 (24—48)  to  35.5
(19—48)
3.9  (3.3-4.6)  to  4.5
(3.5—5.0)
—
Jabbour
et  al.  [15]
2007  6  100  68  ±  58  days —2.1  ±  3.3  (0.93—6.5) —    +0.58  (−1.1—1.3) Three  transplanted
Lewis  et  al.
[16]a
2007  34  49  ±  6 12 weeks 4.25  ±  0.5  to  3.5  ±  0.2 30  ±  2  to  28  ±  2 —  No  death  reported
Perez-Villa
et  al.  [22]
2010  7  174  16  weeks 4.9  ±  1  to  3.4  ±  1 48 ±  8  to  43  ±  9 4.5  ±  1.6  to  5.7  ±  1.9 Seven  transplanted
Dumitrescu
et  al.  [17]
2011  9  60  19.7  ±  6.9
months
9.5 ±  1.8  to  4.4  ±  0.7 53.0  ±  1.8  to  35.8  ±  3.9 3.5  ±  0.4  to  3.6  ±  0.3 —
De  Santo
et al.  [23]
2012  31  225  3  months  6.6  ±  4  to  5.41  ±  3  46.5  ±  6  to  37.1  ±  7  3.43  ±  0.5  to  3.51  ±  0.4  31  transplanted;  one
in-hospital  death
Potter  et  al.
[19]
2012  16  102.5  ±  54.0  6  months  4.8  (3.0—5.9)  to  2.8
(2.1—4.4)
37.5  (34.5—44.5)  to
33.5  (25.5—44.8)
1.5  (1.3—1.6)  to  1.8
(1.5—2.3)b
Eight  transplanted;  two
removed;  no  death  reported
Pons  et  al.
[18]
2012  15  109  ±  42 163  ±  116  days 5.0  ±  1.1  to  3.0  ±  1.6 43.9  ±  12.5  to
33.4  ±  5.8
3.43  ±  0.6  to  3.9  ±  1.3  15  transplanted;  two
in-hospital  deaths
Reichenbach
et  al.  [20]
2013  32  73  ±  25 101  ±  34  months 5.5  ±  1.9;    —32% 47  ±  6.7 3.6  ±  0.8;    +15% Two  deaths;  19  transplanted;
two  LVADs;  11  removed  or  on
list
Our  study 2014  18  92  ±  37 8.72  (4.4—13.5)
months
5.3  ±  1.9  to  3.3  ±  1.8 45  ±  6  to  41  ±  11 3.32  ±  0.85  to
3.83  ±  0.92
Five  deaths;  eight
transplanted;  three  LVADs;
three  heart  failure  deaths;
two  on  list;  two  removed
: difference; LVAD: left ventricular assist device; mPAP: mean pulmonary artery pressure; PVR: pulmonary vascular resistance; WU: Wood units.
a Double-blind versus placebo randomized study.
b Cardiac index.
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ccording  to  PVR  after  sildenaﬁl.  Three  patients  had  UNOS1
rgent  heart  transplantation  (one  of  whom  died  during
he  postoperative  period),  two  had  a  successful  non-urgent
ransplantation,  six  patients  received  an  LVAD  (one  of  whom
ied  during  the  postoperative  period),  three  patients  died
rom  heart  failure  and  four  patients  improved  (two  of
hese  patients  were  withdrawn  from  the  waiting  list  for
eart  transplantation  because  of  a  dramatic  and  persistent
mprovement  [after  4.5  and  2.5  years]).
All  patients  had  PVR  >  3  WU  before  sildenaﬁl  and  nine
atients  had  PVR  >  3  WU  after  sildenaﬁl  therapy,  two  of
hom  had  persistent  PVR  >  3  WU  during  dobutamine  infu-
ion.  All  the  patients  with  PVR  <  3  WU  after  sildenaﬁl  were
live,  compared  with  four  in  the  other  subgroup  (44%  sur-
ival).  In  patients  with  PVR  >  3  WU  after  sildenaﬁl,  the  two
atients  with  persistent  elevated  PVR  during  dobutamine
nfusion  died,  compared  with  three  of  the  seven  patients
ho  had  PVR  <  3  WU  during  dobutamine  infusion.  The  ﬁve
atients  who  died  had  the  highest  PVR  after  sildenaﬁl  treat-
ent  (from  4.64  to  6.47  WU).  One  young  patient  (age  44
ears)  with  PVR  >  3  WU  after  sildenaﬁl  treatment  died  of
ultiorgan  dysfunction  and  sepsis  during  the  postopera-
ive  period  after  heart  transplantation.  Baseline  PVR  was
nchanged  after  sildenaﬁl  treatment  (5.40  to  5.66  WU).
owever,  PVR  during  dobutamine  infusion  was  lower  after
ildenaﬁl  (6.19  to  2.62  WU).  mPAP,  transpulmonary  gradi-
nt  and  diastolic  pulmonary  gradient  were  not  helpful  for
isk  stratiﬁcation  of  the  patients.  Ultimately,  six  patients
ere  successfully  transplanted,  three  patients  had  a  deﬁni-
ive  LVAD  implantation,  two  patients  were  withdrawn  from
he  waiting  list  for  heart  transplantation,  and  two  improved
nd  were  still  on  the  waiting  list  (72%  survival).  Sildenaﬁl  was
ell  tolerated,  without  any  complications  —  in  particular,  no
ystemic  hypotension.
istorical cohort
he  18  patients  in  the  study  population  were  compared  with
he  18  previous  patients  with  the  same  inclusion  criteria
een  between  1999  and  2006.  The  mean  age  of  these  ‘histori-
al  patients’  was  49  ±  8  years  (P  =  0.74),  four  were  women,
1  had  ischaemic  cardiopathy,  two  patients  had  atrial  ﬁb-
illation,  ﬁve  had  diabetes  mellitus,  ﬁve  had  complete  left
undle  branch  block  (one  of  whom  had  resynchronization
herapy)  and  11  patients  had  an  implantable  deﬁbrillator.
ajor  clinical  characteristics  and  the  treatment  of  these
atients  are  presented  in  Table  1.  Haemodynamic  data  were
imilar  (Table  2).  After  a  median  follow-up  period  of  1.46
1.16—2.50)  years,  all  the  patients  had  died:  six  sudden
ardiac  deaths  (three  of  whom  had  an  implantable  deﬁb-
illator),  nine  heart  failure  deaths,  two  non-cardiac-related
eaths  and  one  death  after  heart  transplantation.  By  com-
arison,  survival  in  our  study  population  was  72%,  with  a
edian  follow-up  period  starting  after  the  ﬁrst  right  heart
atheterization  of  1.34  (1.05—2.50)  years  (P  =  0.41).
iscussione  found  a  signiﬁcant  improvement  in  haemodynamic  varia-
les  after  sildenaﬁl  treatment,  with  a  particularly  notable
ecrease  in  PVR.  The  decrease  in  PVR  was  mainly  related  to
w
v
p
bP.  de  Groote  et  al.
 vasodilator  effect  of  sildenaﬁl  in  the  pulmonary  circula-
ion,  demonstrated  by  an  increase  in  cardiac  index  without
ncrease  in  pulmonary  pressure  or  PAWP.  All  patients  who
ad  a  signiﬁcant  response  to  sildenaﬁl  with  a  decrease  in
VR  <  3  WU  were  alive  at  follow-up.  In  the  nine  patients
ith  PVR  > 3  WU  after  sildenaﬁl,  dobutamine  infusion  during
ight  heart  catheterization  was  associated  with  a  signiﬁcant
ecrease  in  PVR  in  seven  patients.  The  two  patients  with
ersistent  PVR  >  3  WU  after  dobutamine  infusion  died,  com-
ared  with  three  patients  who  had  a  decrease  in  PVR  <  3 WU.
f  interest,  the  ﬁve  patients  who  died  had  the  highest
VR  after  sildenaﬁl  (>  4.5  WU),  and  four  of  them  did  not
espond  to  sildenaﬁl,  with  greater  PVR  after  than  before
ildenaﬁl  treatment.  Finally,  we  had  72%  survival  in  a  severe
ubgroup  of  patients  with  chronic  heart  failure.  We  can-
ot  exclude  a  combined  effect  of  sildenaﬁl  and  diuretics,
s  doses  of  diuretics  were  modestly  increased  after  the
rst  right  heart  catheterization.  However,  right  atrial  pres-
ures  were  similar  before  and  after  sildenaﬁl,  suggesting
hat  the  increase  in  the  doses  of  diuretics  had  minimal
ffects  on  pulmonary  and  cardiac  haemodynamics.  Another
ossible  therapeutic  option  in  patients  with  severe  chronic
eart  failure  is  to  reduce  doses  of  beta-blockers  in  order  to
ncrease  heart  rate  and  cardiac  index.  However,  no  study  has
xamined  this  alternative  therapeutic  option.  Moreover,  a
ecent  analysis  in  patients  with  pulmonary  arterial  hyperten-
ion  failed  to  demonstrate  a  harmful  effect  of  beta-blocker
herapy  [13].
Other  previous  studies  looking  at  the  chronic  effect  of
ildenaﬁl  in  patients  with  severe  LVSD  were  small  stud-
es,  from  case  reports  to  studies  that  included  no  more
han  31  patients  [14—23].  The  main  results  of  these  stud-
es  are  summarized  in  Table  3;  they  were  all  open-label,
xcept  for  the  study  by  Lewis  et  al.  [16].  All  of  these
tudies  demonstrated  signiﬁcant  and  favourable  effects  on
aemodynamic  variables,  which  were  translated  into  clini-
al  improvement  in  most  cases.  In  the  study  by  Lewis  et  al.,
4  patients  were  randomized  to  12  weeks  of  treatment
ith  sildenaﬁl  or  placebo.  Sildenaﬁl  was  associated  with
 signiﬁcant  decrease  in  PVR  at  rest  and  during  exercise
ompared  with  placebo,  with  a signiﬁcant  increase  in  both
ardiac  output  during  exercise  and  exercise  capacity.  Silde-
aﬁl  also  improved  right  ventricular  ejection  fraction.  Other
tudies  in  patients  with  persistent  pulmonary  hypertension
fter  LVAD  implantation  have  found  a  signiﬁcant  decrease
n  pulmonary  pressures  with  sildenaﬁl  therapy  [24].  Sev-
ral  double-blind  placebo-controlled  trials  in  patients  with
hronic  heart  failure,  but  without  haemodynamic  inclusion
riteria,  have  analysed  chronic  administration  (up  to  one
ear)  in  fewer  than  55  patients  with  chronic  heart  fail-
re.  In  these  studies,  sildenaﬁl  demonstrated  a  signiﬁcant
ncrease  in  exercise  capacity  and  favourable  effects  on  car-
iac  remodelling  [25,26].  However,  in  a  recent  double-blind,
lacebo-controlled  study  in  patients  with  heart  failure  with
reserved  ejection  fraction,  sildenaﬁl  failed  to  demonstrate
ny  signiﬁcant  effect  on  exercise  capacity  [27]. In  our  study,
xcept  for  New  York  Heart  Association  functional  classiﬁca-
ion,  VE/VCO2 slope  and  right  ventricular  ejection  fraction,
e  did  not  ﬁnd  any  signiﬁcant  modiﬁcation  to  any  other
ariable  after  sildenaﬁl.  This  is  not  surprising,  because  our
atients  had  very  severe  heart  failure  and  because  the  time
etween  the  two  evaluations  was  short.
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We  compared  our  study  population  with  a  ‘historical’
cohort.  There  were  some  minor  clinical  differences  but  the
haemodynamic  data  were  similar.  However,  we  did  not  con-
trol  right  heart  catheterization  in  the  ‘historical’  patients.
Thus,  we  do  not  have  the  natural  evolution  of  haemody-
namic  data.  It  is  very  difﬁcult  to  compare  survival  in  these
two  populations  because  the  therapeutic  management  has
changed.  The  percentage  of  patients  with  implantable  deﬁb-
rillators  was  lower  in  the  ‘historical’  cohort  compared  with
in  the  study  population,  explaining  the  high  rate  of  sudden
cardiac-related  death.  Moreover,  an  LVAD  was  not  routinely
implanted  as  a  destination  therapy.  All  patients  from  our
‘historical’  cohort  died  during  a  short  follow-up  period  (1.13
[0.36—2.67]  years)  compared  with  28%  in  our  study  popula-
tion  (1.46  [1.1—2.67]  years).
Sildenaﬁl  is  extensively  prescribed  in  patients  with  pul-
monary  arterial  hypertension.  Currently,  in  patients  with
post-capillary  pulmonary  hypertension,  we  are  starting
sildenaﬁl  only  in  those  selected  for  heart  transplantation
or  before  LVAD  implantation  in  case  of  contraindication  to
heart  transplantation.  We  do  not  have  any  data  concerning
the  long-term  safety  of  sildenaﬁl  in  patients  with  LVSD,  and
we  discourage  the  off-label  prescription  of  sildenaﬁl  in  other
subgroups  of  patients  with  chronic  heart  failure.
Study limitations
The  major  limitation  of  the  present  study  was  that  it
was  not  placebo-controlled.  As  in  previous  studies,  we
report  our  clinical  experience  in  a  very  speciﬁc  subgroup
of  patients  —  young  heart  transplant  candidates  with  severe
pulmonary  hypertension.  However,  all  patients  underwent
the  same  protocol  before  and  after  the  introduction  of  silde-
naﬁl  and,  particularly,  the  same  haemodynamic  evaluation.
Conclusion
In  this  open-label  study  in  patients  with  severe  LVSD  and
pulmonary  hypertension,  sildenaﬁl  was  associated  with  a
signiﬁcant  decrease  in  PVR.  Survival  was  better  in  patients
who  had  a  decrease  in  PVR  with  sildenaﬁl.  Further  studies
are  required,  particularly  a  double-blind  placebo-controlled
trial,  to  determine  exactly  the  effects  of  sildenaﬁl  in
patients  with  severe  chronic  heart  failure.
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